GFAP and Parkinson disease: The treatment with the GFAP-TH plasmid encapsulated in OX26 TfRMAb-THLs normalized the immunoreactive TH in striatum of the PD rats (Figure 17V,X), whereas there was no therapeutic effect in PD rats treated with the GFAP-TH plasmid encapsulated in IgG2a-THLs (Figure 17W,Y).